Tag: #ESAs
-
How Secondary Hyperparathyroidism Treatment Improves Hemoglobin Levels and Reduces ESA Dependency in Hemodialysis Patients
IntroductionSecondary hyperparathyroidism (SHPT) is a common but often overlooked factor contributing to anemia in hemodialysis (HD) patients. A recent study examined the impact of SHPT treatment on hemoglobin levels and the need for erythropoiesis-stimulating agents (ESAs). Understanding this connection can help improve anemia management in HD patients. Visit https://www.clinnephrologyjournal.org/jcn for more groundbreaking research in nephrology.…
Heighten Science Publications Inc. 